2 April 2019
BDA advises Quasar Medical on sale of majority stake to Longreach
Divested majority stake to The Longreach Group
BDA Partners is pleased to announce that its client, Quasar Medical, has agreed to sell controlling interests in Quasar Engineering Ltd and QIL Engineering Ltd to the Asia-focused private equity fund, The Longreach Group. Terms of the transaction were not disclosed.
Established in 1988 and headquartered in Hong Kong, Quasar is a leading contract development and manufacturing organization (“CDMO”) of advanced medical devices for blue-chip medtech leaders such as Johnson & Johnson and Medtronic. With two modern facilities in China and a presence in Israel, Quasar leverages its unique footprint, process know-how and differentiated manufacturing capabilities to commercialize some of the most complex and mission-critical minimally-invasive devices on the market.
BDA Partners was the exclusive financial advisor to Quasar on the transaction.
Boaz Amitai, Chairman, Quasar Medical, commented: “We are delighted to partner with Longreach, who understands our values, shares our ambitions, and brings valuable experience to us at this pivotal stage in our evolution. This partnership will allow Quasar to address a variety of compelling growth opportunities with our key customers, while enhancing our platform to continue delivering best-in-class outcomes. We’re excited to be working with Longreach and look forward to advancing our mission of unparalleled service to the medical devices industry through the stronger organization we will build together.”
"BDA is proud to have worked with Quasar to consider and optimize its strategic options, bringing our expertise in the medtech space and in cross-border Asian M&A to this transaction. Building a company in Asia that supports the development of true, global innovation in medical devices has been a great achievement for the Amitai family and we wish them and Longreach every success."
About Quasar Medical
Quasar specializes in the manufacture of products for the medical device market, e.g. catheters, electronics and disposables. Founded in Hong Kong in 1988 by Boaz Amitai, Quasar provides its customers with a full turnkey solution for the entire production process, from the transfer-to-production stage through the production process itself to product delivery.
Quasar is distinctive in its proven ability to manufacture in China, resulting in significant advantages (in costs, manpower, timing), in tandem with its advanced engineering technology, international quality standards of production, and strict control in the field of IP. Quasar’s engineering and technological capabilities, such as microscope assembly and clean-room manufacturing, have made it a market leader in the area of manufacturing medical devices and won it the loyalty of the world’s leading medtech companies. quasar-med.com
About The Longreach Group
The Longreach Group is an established independent private equity firm with offices in Hong Kong and Tokyo. The firm focuses on Japan and related Greater China control buyouts in the mature industrial and technology, consumer, business services and financial services sectors. The firm manages three Funds which have accumulated approximately US$2.1bn of committed limited partner and co-investment capital and has a strong track record of portfolio company value creation and realizations.
The Longreach Group Companies include the funds that serve as the investment companies, The Longreach Group Limited, which is based in Hong Kong, and The Longreach Group, Inc. which is based in Tokyo, Japan. The Longreach Group, Inc. collects and analyses data and information concerning the Japanese and Asian markets and assists The Longreach Group Limited in identifying potential investment opportunities. longreachgroup.com
BDA Partners is the global investment banking advisor for Asia. We are a premium provider of Asia-related advice to sophisticated clients globally, with over 20 years’ experience advising on cross-border M&A, capital raising, and financial restructuring. We provide global reach with our teams in New York and London, and true regional depth through our seven Asian offices in Mumbai, Singapore, Ho Chi Minh City, Hong Kong, Shanghai, Seoul, and Tokyo. BDA has deep expertise in the Chemicals, Consumer & Retail, Health, Industrials, Services and Technology sectors. We work relentlessly to earn our clients’ trust by delivering insightful advice and outstanding outcomes.
BDA Partners has strategic partnerships with William Blair, a premier global investment banking business, and with DBJ (Development Bank of Japan), a Japanese Government-owned bank with US$150bn of assets.
US securities transactions are performed by BDA Partners’ affiliate, BDA Advisors Inc, a broker-dealer registered with the Securities and Exchange Commission (SEC). BDA Advisors Inc is a member of the Financial Industry Regulatory Authority (FINRA) and SIPC. In the UK, BDA Partners is authorised and regulated by the Financial Conduct Authority (FCA). In Hong Kong, BDA Partners (HK) Ltd is licensed and regulated by the Securities & Futures Commission (SFC) to conduct Type 1 and Type 4 regulated activities to professional investors. www.bdapartners.com
Divested Escientia Life Sciences to Deccan Fine Chemicals
Divested significant stake in Kehua Bio-Engineering to Gree Real Estate
Divested LAP Laser to IK Investment Partners
Divested plant health business in Japan to Nisso
Divested The Ritedose Corporation to AGIC and Humanwell
Majority recapitalized by Galen Partners
Divested CMC Biologics to Asahi Glass
Acquired Graphic Controls, USA
Divested to a Japanese chemicals & life science company
Sold stake in An Giang Plant Protection to Standard Chartered
Acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
Divested Shanghai Elsker Mother & Baby Co. Ltd to Johnson & Johnson
Divested Radiant Research Inc, US-based clinical research company
Divested medical supply business to Halma in the UK
Established an animal vaccine JV with Jilin Guoyuan Animal Health
Acquired Lablndia distribution business in India
Divested Swine MH vaccine business in China to Harbin Pharmaceutical group